Trial NCT02302339

View at ClinicalTrials.gov 
Org. Study IDs: CDX011-05

Last trial update was posted on 2019-09-06

MeSH Interventions

Antibodies, Monoclonal Glembatumumab vedotin Nivolumab Pembrolizumab

MeSH Conditions

Melanoma

Other Conditions


Stopping Reasons

Development of glembatumumab vedotin was discontinued

Limitations And Caveats

Study was discontinued early, leading to small number of subjects analyzed in Cohort 4 and minimal patient follow up in Cohorts 3 and 4.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID